Cosentyx vs Stelara
Side-by-side cost comparison based on Medicare Part D data
Cosentyx
Secukinumab
Manufactured by Novartis
Stelara
Ustekinumab
Manufactured by Janssen
Cosentyx costs 53% less per claim than Stelara ($3,616.00 vs $7,763.00). A generic version of Cosentyx is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Cosentyx | Stelara |
|---|---|---|
| Avg Cost Per Claim | $3,616.00 | $7,763.00 |
| Total Medicare Spending | $3.1B | $5.6B |
| Total Beneficiaries | 120,000 | 114,000 |
| Total Claims | 864,000 | 720,000 |
| Annual Cost/Patient | $26,033.00 | $49,026.00 |
| Year-over-Year Change | +8.9% | +6.3% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Novartis | Janssen |
| Condition | Autoimmune Diseases | Autoimmune Diseases |
| Generic Name | Secukinumab | Ustekinumab |
Cosentyx vs Stelara: What the Data Shows
Cosentyx (Secukinumab) and Stelara (Ustekinumab) are both used to treat autoimmune diseases. Based on Medicare Part D data, Cosentyx costs $3,616.00 per claim, which is 53% less than Stelara at $7,763.00 per claim.
Medicare spent $3.1B on Cosentyx and $5.6B on Stelara. In terms of patient reach, Cosentyx serves more beneficiaries (120,000 vs 114,000).
Year-over-year spending changed +8.9% for Cosentyx and +6.3% for Stelara.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Cosentyx is cheaper at $3,616.00 per claim, compared to $7,763.00 for Stelara. That makes Cosentyx about 53% less expensive per claim based on Medicare Part D data.
Yes, both Cosentyx and Stelara are used to treat autoimmune diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Secukinumab and generic Ustekinumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $3.1B on Cosentyx covering 120,000 beneficiaries, and $5.6B on Stelara covering 114,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.